India, Sept. 28 -- Kodiak Sciences Inc. (KOD) is up 144.68 percent, gaining $46.81 to $79.15 on Monday. The move comes after the biotechnology company announced that both Zenkuda and tabirafusp-ted met the primary endpoints in the Phase 3 DAYBREAK study in patients with wet age-related macular degeneration, with both treatments demonstrating non-inferiority in vision gains compared with aflibercept at year one.
Kodiak Sciences is currently trading at $79.15, up from the previous close of $32.35 after opening at $61.28 on the Nasdaq. The stock has traded between $60.50 and $87.83 during the session, with trading volume at 21.29 million shares versus an average volume of 701,082 shares.
Zenkuda delivered rapid clinical effects during the lo...